Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMO, ADXS does not need a BO...
ADXS needs a momentum on the upside....
"Why would it break $3.10 or fly, until the cash issue is fixed and $1 dilution is off the table? "
Remember 2015 when ADXS went from $2 to $30 in less than 2 months?
The 200 day moving average falls under technical analysis, and technical analysis does not care about cash on hand, FDA hold, or dilution....
That's how bots and traders and shorties work for the most part IMO
IMO, The only thing ADXS needs to break is the 200 day moving average of $3.10...
After that, ADXS will fly (IMO)
Yea, lunch is always dangerous for ADXS, but I'll take a green close
ADXS has Price rise and 100k+ volume in the first hour...
COMECER AMERICA signs a new agreement for the production of an aseptic manufacturing system (isolator technology) for Advaxis
New agreement beeetwen ADVAXIS and Comecer Pharma Isolator
COMECER (Castel Bolognese, RA, ITALY) together with its US subsidiary COMECER Inc. (Norristown, PA, USA) and Advaxis, Inc. (Princeton, NJ, USA), entered into an agreement for the production of an aseptic manufacturing system based on COMECER proprietary Isolation Technology, to be deployed for the development of Immunotherapies according to the Advaxis technology.
The system will be developed in the Italian COMECER facilities and will allow Advaxis to perform their unique Lm targeted Immunotherapy aimed at the production of a neoantigen immunotherapy, integrated within COMECER GMP grade isolation technology devices.
According to the process, the system will be used for processing and expanding attenuated strains of Lm, which will be then bioengineered to secrete an antigen-adjuvant fusion protein.
The preparation is then infused in the patient, creating potent innate immune stimulation. Due to the flexibility and adaptability of the platform and the manufacturing, the process can be adapted to target many different tumor types.
The system is being delivered as a combination of COMECER Isolators and the unique Flexycult mobile incubation
system, along with the integration of several other typical cell-processing laboratory devices. All the devices installed within the isolators respond to the highest standards for laboratory equipment and have been specially adapted for use in isolators.
Alessia Zanelli, CEO of Comecer Group: “When our equipment is used for such an important medical project, all of us at Comecer are proud. Being selected by Advaxis speaks to the quality of our solutions and confirms that our R&D investments are going in the right direction.”
Source:
https://www.comecer.com/comecer-america-signs-agreement-production-aseptic-manufacturing-system-isolator-technology-advaxis/
IMO, the volume and chart indicate that the market is begging for an excuse to rise up ADXS price...
And ADXS Management has gone dead silent after the recent preclinical news...
How do you know Ken opened the emails?
I was just trying to say that contacting these guys to get attention towards ADXS is useless cuz they ignore is anyway... so no need to waste time
And I used Sarissa as example, someone from this message board contacted Sarissa to have more stake or control in ADXS and Sarissa closed out 100% later on....
Last time someone from this board reached out to Sarrisa and they sarrisa closed out of ADXS....
It's a company called Engaged Capital
Engaged Capital Nominates Three to ARATANA THERAPEUTIC's (PETX) Board
April 5, 2018 9:10 AM
In a 13D filing on ARATANA THERAPEUTIC (NASDAQ: PETX), hedge fund Engaged Capital LLC disclosed a 5.2%, or 2,400,000 share, stake in the company.
Source
https://www.streetinsider.com/dr/news.php?id=14026243
ADXS needs an activist investor to question ADXS Management, that will lift ADXS PPS for sure....
Case in point, PETX went from $10 down to $3... activist investor joined and now it's at $5+ in the uptrend
"you have to assume that management knows more than we do and they can do simple math just as well as we can"
YES, THAT IS A CFO'S JOB!
so where is ADXS CFO? They promised to announce a new one when Sara would leave end of April....
ADXS chart is still a higher high and a higher low...
So long as the trend is up direction, I can be patiently happy!
MRK & BMY are freeloading....
If ADXS-PSA needs to go any further, MRK needs to pay or ADXS needs to save money and reduce burn rate IMO
Thanks for this excellent post / lesson hovacre!
And don't forget ADXS-DUAL..
Now that would be competition to MRK....
MRK, BMY & AMGEN are all in play with ADXS!
Yep, that is exactly it hdwrsft, ADXS treatment would be required for everyone who clears first round to prevent a recurrence
Hovacre,
What does response rate mean? And how is it different from stabilized disease?
In addition to Dew's comment, MRK and ADXS are technically not competing on HPV treatment ...
ADXS phase 3 trail is unique in that it is designed to prevent recurrence....
No one else is running a trial on recurrence!
Yep... it's Tom Petty
Yes, Adage Dumped another 500k...
So we got:
ADAGE with 3.5 million ADXS shares
BlackRock with 2.9 Million
Vanguard with 1.9 million
Renaissance with 0.99 million
State Street with 0.67 million
Good observation James...
Top 5 ADXS holders now includes Renaissance and Fidelity/FMR is now he top 6th holder
"Just throwing this out there.......what's the probability of this being at $15 by end of June?"
Let's see:
1. ADXS-PSA data
2. ADXS NEO start and some money from AMGN
3. ADXS HOT IND
4. ADXS ADVANCE OR DUAL IND
5. EU deal with upfront cash
6. More partnerships ? AXAL or HOT?
7. Maybe warrants in the money translating into more Cash on Hand
All of this can play into a VERY HIGH probability of $15...
So I would guess as 80%
Unfortunately nothing mentioned in the 10Q of PETX.... so I got no timeline...
Don't see any, but a worthy observation is BlackRock loading up like crazy...
2018-05-09 13F-HR shows that BlackRock went from 2.2 million ADXS share to 2.9 million shares
"Europe, positive news on canine, and hold lifted....should be notable positives for PPS...I am optimistic "
I skimmed thru the newly released PETX 10Q, no real dates on AT-014, just a mention that two dozen sites are now using AT-014 and that the study will pay for itself, which is good.
"The sp of the common stock will have to be close to $10 for the warrants to be in the money by Oct. "
Can you explain what the above statement means?
If the warrant conversion to stock is $5 so anything over $5 is in the money... why do you say $10?
"if you buy a warrant now at $0.30, do you have to pay another $5 to get a share if they do happen to end up in the money?"
Yes that is correct husker.
1 warrant gives you an option to buy 1 share at $5
ADXS made a higher high... that's a step in the right direction
Good video link, thanks hdwrsft
Thanks Dew.
Yep, I think it's only a matter of ADXS breaking the 200 Day Moving Average of $3.44...
Once ADXS breaks $3.44, the. We keep flying with no boundaries
ADXS getting close to breaking out... if it closes above $1.85... ADXS will have a new Monthly High!
Can someone try to explain the following in simple English?
“We also saw potent immune responses targeting frameshift mutations and control of tumor growth via multiple complementary mechanisms. This is important because frameshift mutations are observed to generate up to nine times more neoantigens per mutation than in-frame mutations”
2 PM today, POTUS is making a speech on drug pricing...
Red day for biotech sector expected.... but let's see how the day goes
ADXS TOP 5 TUTE HOLDERS
ADAGE 4,000,000
BlackRock Inc. 2,281,216
VANGUARD GROUP INC. 1,965,538
STATE STREET CORP. 646,922
FMR LLC / Fidelity. 542,230
Tony knew he was interim, so no motivation to deliver.
Ken is permanent CEO, so at the very least he is expected to try harder than LomBado.
Plus: with ROSG failure, Ken's reputation is at stake as a CEO to the biotech industry. So Ken must deliver!
Agree on what you state is true.
Here is what I was really trying to state:
If Ken dilutes at a higher share price or gets upfront cash through a deal (even though Ken has the option to dilute at all time low), THEN he can be credible IMO and time will tell.
IMO tutes leave and shorty hold and market's hate on ADXS was partly due to missing permanent leadership.
At minimum, I am glad that there is now a permanent leader (and not an interim one).